

## References

I-146

1. Ortega H, Liu M, Pavord I, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *New Engl J Med*. 2014; 371(13):1198-1207.
2. Prazma CM, Wenzel S, Barnes N, et al. Characterisation of an oral corticosteroids (OCS)-dependent severe asthma population treated with mepolizumab. *Thorax*. 2014; 69(12):1141-1142.
3. Katz, L, Gleich G, Hartley B, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. *Annals Am Thor Soc*. 2014;11(4):531-536.
4. Chung KF, Wenzel SE, Brozek JL, et al. International European Respiratory Society/American Thoracic Society guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014; 43(2):343-373.
5. GlaxoSmithKline LLC, (NUCALA) package insert. Philadelphia, PA. December 2017.
6. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2012;456-463.
7. Teva Branded Pharmaceutical Products, R&D Inc. A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma. Available from: <https://clinicaltrials.gov/ct2/show/NCT01270464>. NLM identifier: NCT01270464.
8. Teva Branded Pharmaceutical Products, R&D Inc. A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma. NLM identifier: NCT01287039.
9. Teva Branded Pharmaceutical Products, R&D Inc. A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma. NLM identifier: NCT01285323.
10. Teva Branded Pharmaceutical Products, R&D Inc. Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma. Available from: NLM identifier: NCT01508936.
11. Bjerner L, Lerniere C, Maspero J, et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels. *CHEST*. 2016 Oct;150(4):789-798.
12. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Benralizumab.
13. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Mepolizumab.
14. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Reslizumab.
15. AstraZeneca Pharmaceuticals LP. Fasentra package insert, Wilmington, DE. November 2017.
16. Teva Pharmaceutical Industries Ltd. Cinqair package insert, Frazer, PA. May 2016.
17. Pham T, Damera G, Newbold P, & Ranade K. Reductions in Eosinophil Biomarkers by Benralizumab in Patients with Asthma. *Respiratory Medicine*. 2016;111:21-29.

18. Goldman M, Hirsch I, Zangrilli J G, et al. The Association Between Blood Eosinophil Count and Benralizumab Efficacy for Patients with Severe, Uncontrolled Asthma: Subanalyses of the Phase III SIROCCO and CALIMA Studies. *Curr Med Res Opin.* 2017 September;33(9):1605-1613.
19. FitzGerald J M, Bleecker, E R, Menzies-Gow A, et al. Predictors of Enhanced Response with Benralizumab for Patients with Severe Asthma: Pooled Analysis of the SIROCCO and CALIMA Studies. *Lancet.* 2018;6:51-64.
20. Wechsler M E, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. *New Engl J Med.* 2017 May;376(20):1921-1932.
21. ClinicalTrials.gov. U.S. National Institutes of Health. Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma. ClinicalTrials.gov Identifier: NCT01238861.
22. ClinicalTrials.gov. U.S. National Institutes of Health. Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting B2 Agonist. ClinicalTrials.gov Identifier: NCT01914757.
23. ClinicalTrials.gov. U.S. National Institutes of Health. Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients with Uncontrolled Asthma. ClinicalTrials.gov Identifier: NCT01928771.
24. ClinicalTrials.gov. U.S. National Institutes of Health. Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients with Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy. ClinicalTrials.gov Identifier: NCT02075255.
25. ClinicalTrials.gov. U.S. National Institutes of Health. Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients with Mild to Moderate Persistent Asthma. ClinicalTrials.gov Identifier: NCT02322775.